secwatch.observer — SEC 8-K summary
======================================

Issuer:     Korro Bio, Inc. (KRRO)
CIK:        0001703647
Form:       8-K
Filed at:   2026-03-12T23:59:59+00:00
Accession:  0001193125-26-104135
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Korro Bio reports FY2025 net loss $117.3M, nominates KRRO-121 for UCD/HE; $85M PIPE extends runway to H2 2028
--------------------------------------------------------------------------------

- FY2025 net loss $117.3M vs $83.6M in FY2024, driven by $30.9M non-cash impairment charges on KRRO-110 termination.
- Cash $85.2M at Dec 31, 2025; plus $85M private placement in Mar 2026 extends runway into H2 2028.
- Nominated KRRO-121 for UCD and HE; regulatory filing expected H2 2026.
- GalNAc AATD program achieved >90% in vivo RNA editing; candidate nomination Q2 2026.
- Collaboration revenue $6.4M from Novo Nordisk (paused); R&D expenses $65.6M, G&A $28.2M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1703647/000119312526104135/0001193125-26-104135-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1703647/000119312526104135/krro-20260312.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-104135

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer